Business Wire

ANT-GROUP

5.7.2024 12:27:25 CEST | Business Wire | Press release

Share
Ant Group Unveils Cloud-based Cryptographic Computing Platform

Ant Group today unveiled SecretFlow Cloud, its cloud-based cryptographic computing platform, and a suite of cryptographic computing solutions tailored for large language models (LLMs) at the World Artificial Intelligence Conference in Shanghai.

Leveraging integrated software-hardware cryptographic computing technologies, these solutions enable the secure circulation of encrypted data throughout the hosting and inference processes of LLMs, safeguarding the integrity of LLM assets and data security while significantly enhancing data privacy protection. Providers can now encrypt and deploy their LLMs onto cloud environments effortlessly with a single click through its encrypted hosting service, safeguarding their valuable assets from compromise and theft. Meanwhile, the encrypted inference service ensures efficient data security and the protection of trade secrets during interactions with LLMs.

These solutions allow GPUs to perform computing tasks within trusted execution environments, notably reducing the cost and performance disparity between encrypted LLM inference and plaintext operations, providing a more cost-effective approach. The platform also integrates additional technologies such as memory and disk encryption, ensuring end-to-end encryption and secure cross-domain model hosting management. Additionally, a user-friendly remote attestation system allows for smooth verification through web interfaces, minimizing friction for users.

SecretFlow Cloud currently supports both public and private cloud deployments, and is compatible with commonly-used LLMs in the global market. For instance, in a public cloud setup, users can seamlessly build a new professional LLM on SecretFlow Cloud or migrate an existing LLM to the platform, with its secure LLM inference services ready in as few as 10 minutes with just a click. Moreover, users can purchase cryptographic computing resources on demand to meet their needs.

"Data is the most critical element in the application of LLMs, and cryptographic computing technology significantly enhances the utility of data in cross-domain scenarios," noted Dr. Lenx Wei, Vice President and Chief Technology Security Officer at Ant Group. "As LLMs evolve toward specialized professional domains and become essential productivity tools, cryptographic computing will play a vital role, particularly in fully unlocking the value of high-quality, domain-specific data sets."

According to Dr. Wei, while companies often deploy LLMs in private environments to address data security challenges, such methods can incur higher operational costs and compromise both service efficiency and quality, ultimately constraining the potential of LLMs. The cryptographic computing solutions offered by SecretFlow Cloud can effectively resolve these issues.

Looking forward, SecretFlow Cloud aims to further develop its cryptographic computing solutions to ensure data security throughout the full lifecycle of professional LLMs, including their creation, deployment, and service delivery.

Ant Group has been exploring privacy-preserving computing technologies since 2016 and released SecretFlow in 2022 as an open-source privacy-preserving computing framework that features an array of advanced technologies, including multiparty computation, federated learning, Trusted Execution Environments, Homomorphic Encryption, and Differential Privacy. Positioned at the forefront of cryptographic computing, SecretFlow Cloud represents a new generation of privacy-preserving computing technology, poised to overcome pain points in security, cost, and accessibility in data circulation. It offers a solution for instantly harnessing data value, akin to turning on a tap. To date, its technologies have been adopted in industries such as insurance, rural finance, healthcare, public services, and marketing.

About Ant Group

Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240705154761/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye